Zai Lab Ltd. (ZLAB)

Market Closed

1 Sep, 20:00

NASDAQ (NMS)

25. 30

-0.16

-0.6284%

After Hours

25. 80

+0.5 +1.9763%

2.95B Market Cap

- P/E Ratio

- Div Yield

979,687 Volume

-3.45 Eps

$ 25.46

Previous Close

Investors:

SRB

+14

Analysts:

Add Transaction

Day Range

25.01 25.57

Year Range

15.96 34.72

Want to track ZLAB and more in your Portfolio? 🎯

Get Started For Free

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

Z.ai's shares rose after the company launched a new AI model that it claimed runs only on Chinese chips. It's the latest indication of China's efforts to ramp up homegrown computing capability.

Cnbc | 5 days ago

Zai Lab: Revenue Growth And Zoci's Upside Optionality

ZLAB has grown from a Greater China licensing platform into a dual-engine biopharma. They have a growing proprietary global pipeline with KarXT and TIVDAK. And management expects product sales to stabilize during 2H2026. Zoci's SCLC and NEC activity looks promising, while their other partnered combo therapies could expand their indications across other treatments.

Seekingalpha | 1 week ago

Zai Lab Q2 Earnings Call Highlights

Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business.

Marketbeat | 3 weeks ago

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 3 weeks ago

Zai Lab Q1 Earnings Call Highlights

Zai Lab NASDAQ: ZLAB reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology and immunology pipeline and pointed to multiple upcoming regulatory and clinical milestones.

Marketbeat | 3 months ago

Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript

Seekingalpha | 3 months ago

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 3 months ago

Zai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases Transcript

Seekingalpha | 4 months ago

Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative

On March 31, Zai Lab Limited stock finally broke out of its downward trend. One of the key factors behind this was the ZLAB announcement of a partnership agreement with Amgen. Moreover, I believe that the growing institutional investors' interest in Zai Lab is also driven by the strong performance of Zejula, Nuzyra, and Xacduro.